Further investigation will be needed to explore the definite mechanism of BICD1-associated survival or therapeutic resistance in GBM cells by connecting with IDH1, EMT, or even dynein-mediated pathway, which may provide more understanding of the pathogenesis and therapeutic resistance in GBMs. The gene discussed is BICD1; the disease is glioblastoma.